Roche spent another $580 million on a new drug

Roche, which has been taking the "small acquisition" route, has recently made another move. Roche has agreed to pay California-based Adleron Therapeutics $580 million to develop new treatments for autoimmune diseases, foreign media reported. Under the terms of the agreement, Adheron shareholders will receive $105 million in cash payments and an additional $475 million in milestone payments.
is known to have developed a technique that destroys immune cell adhesion, which is linked to a cell surface protein called Cadherin-11. The technology promises to develop potential therapies for a variety of inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrosis. The company's humanized monoclonal antibody SDP051, which targets Cadherin-11, has completed Phase I clinical trials.
SDP051 is fully humanized using Adheron's CompanyHuman Antibody technology. "We are very excited about this acquisition, which combines Adhenon's in-depth understanding of Cadherin-11 science with Roche's extensive experience in developing the next generation of drugs," said Hari Kumar, CEO of Adheron. In
, Roche made three acquisitions. On the 13th, Roche announced its proposed $425 million acquisition of GeneWEAVEBioSciences, a privately held company, to strengthen its product line in the field of clinical microbiology. On the 19th, Roche agreed to acquire Kapa Biosystems, a company focused on developing NGS, PCR and real-time PCR optimization enzyme-related technologies. On the 24th, Roche announced that it had signed an agreement with Lumora to acquire Lumora's nucleic acid purification technology for sequencing sample preparation. (Medical Valley)